Biotechnology company Imugene (ASX:IMU) said the first patient was dosed in the intratumoral combination group of phase 1 clinical trial on its oncolytic virotherapy candidate, CD19, according to a Monday filing with the Australian bourse.
The study is part of the company's Oasis trial, which aims to evaluate the safety and efficacy of CD19 in patients with advanced or metastatic solid tumors, the filing said. It will explore the direct administration of CD19 into the tumor, as well as intravenous infusion.
The trial is being conducted at seven US sites, with the potential to open a total of 10 sites to recruit up to 40 patients, according to the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.